home / stock / ewtx / ewtx news


EWTX News and Press, Edgewise Therapeutics Inc. From 06/16/22

Stock Information

Company Name: Edgewise Therapeutics Inc.
Stock Symbol: EWTX
Market: NASDAQ
Website: edgewisetx.com

Menu

EWTX EWTX Quote EWTX Short EWTX News EWTX Articles EWTX Message Board
Get EWTX Alerts

News, Short Squeeze, Breakout and More Instantly...

EWTX - New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

- Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Ed...

EWTX - Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2022 Update

Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...

EWTX - Edgewise Therapeutics (EWTX) Investor Presentation - Slideshow

The following slide deck was published by Edgewise Therapeutics, Inc. in conjunction with this event. For further details see: Edgewise Therapeutics (EWTX) Investor Presentation - Slideshow

EWTX - Edgewise Therapeutics GAAP EPS of -$0.30 misses by $0.02

Edgewise Therapeutics press release (NASDAQ:EWTX): Q1 GAAP EPS of -$0.30 misses by $0.02. Cash, cash equivalents and marketable securities of $265.8 million as of March 31, 2022 For further details see: Edgewise Therapeutics GAAP EPS of -$0.30 misses by $0.02

EWTX - Edgewise Therapeutics Reports First Quarter 2022 Financial Results

– Completed enrollment of the ARCH open label study of EDG-5506 in Becker muscular dystrophy (BMD) – – Enrollment initiated in Edgewise-funded Natural History Trial of BMD – – Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD...

EWTX - Edgewise Therapeutics to Present at Upcoming Investor Conferences

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in fireside...

EWTX - Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling

- Trial to inform the disease progression of individuals with BMD - Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today an...

EWTX - Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2021 Update

Halvorsen's 13F portfolio value decreased from $36.04B to $34.49B this quarter. The number of positions increased from 96 to 107. Viking Global added Twilio, Workday, and Aon plc while dropping Fidelity National Information Services and Snowflake. The top three positions are Ginkg...

EWTX - Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference

– Podium presentations on March 15 and 16, 2022 – – Company to host a conference symposium to discuss its new approach to protecting dystrophic muscle featuring a key opinion leader – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical...

EWTX - Edgewise Therapeutics GAAP EPS of -$0.26 beats by $0.02

Edgewise Therapeutics press release (NASDAQ:EWTX): Q4 GAAP EPS of -$0.26 beats by $0.02. “2021 was a tremendous year for Edgewise starting with our successful initial public offering that provided financial stability to grow our talented team and advance our pipeline of product candida...

Previous 10 Next 10